1 Waagstein F. Efficacy of beta blockers in idiopathic dilated cardiomyopathy andischemic cardiomyopathy. Am J Cardiol, 1997, 80(9B): 45J
2 Doughty RN, Rodgers Sharpe N, e t al. Effects of beta-blocker therapy on mortality in patients with heart failure. A systemic overview of randomized controlled trials. Eur Heart J, 1997, 18: 56
3 CIBIS Investigators and Committees. A randomized trial of β blockade in heart failure: the Cardiac Insufficiency Bisoprolo Study (CIBIS). Circulation, 1994, 90: 1765
4 Packor M, Bristow MR, Cohn JN, et al, The effect of carvedilolon morbidity and mortality in patients with chronic heart failure. N Eng1 J Med, 1996, 334: 1349
5 Colucci WS, Packer M, Bristow M R, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of hart failure. Circulation, 1996, 94(11): 2800
6 Andersson B, Lomsky M, Waagstein F. The link betweenacute hemodynamic adrenergic beta-blockade andlong-term effects in patients with heart failure – a study on diastolic function, heart rate and myocardial metabolism following intravenous metoprolol. Eur Heart J, 1993; 14: 1375
7 Gilbert EM, Anderson JL, Deitchman D, et al. Long-term β- blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double blind, randomized study of bucindolol versus placebo. Am J Med, 1970; 88: 223
8 Dasgupta P, Broadhurst P, Lahiri A. The effects of intravenous carvedilol a new multiple action vasodilator beta-blocker, in congestive heart failure. J Cardio vasc pharmacol, 1991; 18(supple 4): S12
9 Bristow MR, O’Connell JB, Gilbert EM, et al, Dose response of chronic β- blocker treatment in heart failure from either idiopathic dilated or ischemic car diomyopathy - Circulation, 1994; 89: 1632
10 AnderssonB, Caidahl K, Dilenarda A, et al. Changes in early and late diastolic filling patterns induced by long-term adrenergic beta-blockade in patients with idiopathic dilated cardiomyopathy. Circulation, 1996; 94: 673
11 Australia-New Zealand Heart Failure Research Group. Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation, 1995; 92: 212
12 Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet, 1993; 342: 1441
13 Bristow MR. Mechanism of action of beta-blocking agents in heart failure Am J Cardiol, 1997; 80(11A): 26L
14 Eichhorn EJ, Bristow M. Practical guidelines for initiationof beth-adrenergic blockade in patients with chronic heart failure. Am J Cardiol, 1997, 79(6):794
15 Eichhorn EJ, Hjalmarson A. β-blockor treatment for chronic heart failure -he Frog Prince. Circulation, 1994; 90: 2153
16 Yoshikawa T, Port JD, Asono K, et al. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J, 1996; 17(suppl B): 8
17 Feuerstein GZ, Ruffolo RR. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur Heart J, 1996, 17(suppl B): 24 |
